OvaScience (OVAS) Rating Lowered to Hold at Zacks Investment Research

OvaScience (NASDAQ:OVAS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday, November 15th.

According to Zacks, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other research firms have also weighed in on OVAS. Oppenheimer restated a “hold” rating on shares of OvaScience in a research note on Thursday, August 3rd. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of OvaScience in a research note on Monday, November 6th.

Shares of OvaScience (NASDAQ:OVAS) opened at $1.52 on Wednesday. OvaScience has a one year low of $1.25 and a one year high of $3.42.

Institutional investors have recently made changes to their positions in the business. Jennison Associates LLC grew its position in shares of OvaScience by 0.4% during the second quarter. Jennison Associates LLC now owns 2,191,258 shares of the biotechnology company’s stock worth $3,418,000 after acquiring an additional 7,731 shares during the last quarter. GMT Capital Corp purchased a new position in shares of OvaScience during the third quarter worth approximately $1,138,000. Sabby Management LLC grew its position in shares of OvaScience by 20.2% during the second quarter. Sabby Management LLC now owns 509,300 shares of the biotechnology company’s stock worth $795,000 after acquiring an additional 85,525 shares during the last quarter. Legal & General Group Plc grew its position in shares of OvaScience by 4,654.1% during the second quarter. Legal & General Group Plc now owns 458,822 shares of the biotechnology company’s stock worth $713,000 after acquiring an additional 449,171 shares during the last quarter. Finally, Broadfin Capital LLC purchased a new position in shares of OvaScience during the second quarter worth approximately $429,000. Institutional investors own 55.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “OvaScience (OVAS) Rating Lowered to Hold at Zacks Investment Research” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://weekherald.com/2017/12/04/zacks-investment-research-lowers-ovascience-inc-ovas-to-hold.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get a free copy of the Zacks research report on OvaScience (OVAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply